- RFP Year2020
- Awarded Amount$710,077
- DiseaseNTD (Chagas disease)
- Development StageTarget Identification
- Collaboration PartnersEisai Co., Ltd., Universidad Nacional de La Plata (UNLP)
Introduction and Background of the Project
There is an urgent need for new treatments for Chagas disease. Existing medications lack effectiveness against chronic infection, require long regimens, and have several adverse effects. Given their integral roles in trypanosome signaling and low homology with human counterparts, phosphodiesterases (PDEs) have been posited as drug targets for Chagas disease. Given the paucity of identified targets and critical need for new mechanism-of-action drugs, these enzymes merit definitive evaluation followed by efficient identification and development of inhibitors.
This project aims to validate PDEs as drug targets for Chagas disease and identify selective inhibitors using a computationally-enhanced screening cascade.
An accelerated drug development path will be sought by focusing on repurposing opportunities that can be rapidly progressed to clinical trials, complemented by screening for new chemical matter from Eisai’s compound library. Candidate inhibitors identified in machine-learning based virtual screens will be profiled experimentally and promising compounds advanced to animal studies.
How can your partnership (project) address global health challenges?
There is an urgent need for development of new treatments for Chagas disease, which affects approximately 7 million people. The two currently approved medications, benznidazole and nifurtimox, were discovered over fifty years ago. These medications require long treatment courses (60-90 days) and cause adverse effects which often result in treatment discontinuation. Furthermore, they lack effectiveness against chronic infection, which is responsible for the majority of mortality and morbidity in Chagas disease. There is a paucity of new drugs under development, exacerbated by the recent failure of CYP51 inhibitors posaconazole and fosravuconazole in clinical trials.
This project seeks to address this pressing need by efficiently developing new compounds with the potential to achieve the target-product-profile for a new Chagas disease drug: a short, well-tolerated treatment that is effective against chronic infection.
What sort of innovation are you bringing in your project?
The project brings together three key elements to tackle the urgent need for new Chagas disease treatments:
First, by conducting conclusive validation of a potential drug target family. The lack of validated drug targets for Chagas disease means thorough exploration of putative targets is vital. Several lines of evidence point to phosphodiesterases (PDEs) as essential proteins in T. cruzi, therefore this project will definitively evaluate three PDE enzymes as drug targets using CRISPR/Cas9 technology.
Second, by harnessing advances in the use of artificial intelligence for drug discovery. Machine-learning models with high predictive power can rapidly screen large compound collections in silico to prioritize compounds for resource-intensive experimental follow-up. Both Eisai and UNLP will bring to bear advanced machine-learning tools in this project, in order to efficiently search chemical space for selective PDE inhibitors cost-effective manner.
Third, by employing a repurposing approach to expedite drug development. Repurposing of approved or shelved compounds with known human safety profiles is a proven strategy to reduce time and risk in drug development. The screening efforts in this project will focus on repurposing libraries to identify compounds with the potential for rapid progression to Phase II proof-of-concept studies. As a practical complement, Eisai’s chemical library will also be screened for new trypanocidal scaffolds.
The innovative approach of the collaboration team leverages the synergy of artificial intelligence, experimental screening capabilities and drug development expertise between a pharmaceutical company and academic investigators in an endemic country.
Role and Responsibility of Each Partner
Eisai will be the project lead and responsible for overall management. Eisai will develop and apply its machine learning capabilities to T. cruzi PDEs, and perform screening against the Eisai compound library. Eisai will further provide PK and safety expertise for evaluation of repurposing candidates, and lead medicinal chemistry activities.
At UNLP, Prof. Talevi’s group will conduct ligand-based machine-learning model development and screening of repurposing libraries, and perform molecular docking simulations. In addition, UNLP will oversee the target validation studies for PDE enzymes using CRISPR/Cas9, the biochemical and whole-cell activity assays, and the in vivo studies in mouse models of Chagas disease.
UNLP will also contribute their experience as investigators in a country where Chagas disease is endemic.